Very long chain fatty acid metabolism is required in acute myeloid leukemia
Matthew Tcheng, Alessia Roma, Nawaz Ahmed, Richard Smith, Preethi Jayanth, Mark D. Minden, Aaron D. Schimmer, David A. Hess, Kristin J. Hope, Kevin A. Rea, Tariq A. Akhtar, Eric Bohrnsen, Angelo D’Alessandro, Al‐Walid Mohsen, Jerry Vockley, Paul A. Spagnuolo
Abstract
Acute myeloid leukemia (AML) cells have an atypical metabolic phenotype characterized by increased mitochondrial mass, as well as a greater reliance on oxidative phosphorylation and fatty acid oxidation (FAO) for survival. To exploit this altered metabolism, we assessed publicly available databases to identify FAO enzyme overexpression. Very long chain acyl-CoA dehydrogenase (VLCAD; ACADVL) was found to be overexpressed and critical to leukemia cell mitochondrial metabolism. Genetic attenuation or pharmacological inhibition of VLCAD hindered mitochondrial respiration and FAO contribution to the tricarboxylic acid cycle, resulting in decreased viability, proliferation, clonogenic growth, and AML cell engraftment. Suppression of FAO at VLCAD triggered an increase in pyruvate dehydrogenase activity that was insufficient to increase glycolysis but resulted in adenosine triphosphate depletion and AML cell death, with no effect on normal hematopoietic cells. Together, these results demonstrate the importance of VLCAD in AML cell biology and highlight a novel metabolic vulnerability for this devastating disease.